格菲妥单抗治疗大B细胞淋巴瘤应答与耐药的分子特征
本研究对接受格菲妥单抗治疗的复发/难治性B细胞非霍奇金淋巴瘤患者外周血单个核细胞进行纵向单细胞RNA测序及功能评估,发现早期维持 naïve 样(更「新鲜」)T细胞状态尤其是新鲜细胞毒性T细胞与临床疗效相关,应答者T细胞功能活性增强;临床前模型显示连续格菲妥单抗治疗联合4-1BB共刺激可增加瘤内新鲜naïve样T细胞比例并增强抗肿瘤疗效。
要点
- 早期维持naïve样新鲜T细胞状态尤其是新鲜细胞毒性T细胞与格菲妥单抗临床疗效相关
- 应答者外周血T细胞功能活性高于非应答者
- 格菲妥单抗联合4-1BB共刺激可增加瘤内新鲜naïve样T细胞并增强抗肿瘤疗效
核心结论
- 新鲜naïve样T细胞状态具有治疗相关性,联合4-1BB共刺激可能克服T细胞衔接器耐药并改善侵袭性淋巴瘤临床应答。
研究设计与样本
- 对格菲妥单抗治疗的复发/难治性B细胞非霍奇金淋巴瘤患者外周血单个核细胞进行纵向单细胞RNA测序分析和功能评估。
- 纳入达到完全代谢缓解或进展性代谢疾病的患者,并分析临床前肿瘤模型患者外周血单个核细胞及瘤内T细胞。
主要发现
- 早期时间点维持naïve样(更「新鲜」)T细胞状态尤其是新鲜细胞毒性T细胞与临床疗效相关。
- 应答者T细胞相比非应答者表现出增强的功能活性。
- 连续格菲妥单抗治疗后患者外周血单个核细胞和临床前模型瘤内T细胞显示持续功能活性。
- 格菲妥单抗联合4-1BB共刺激增加瘤内具有新鲜naïve样表型的T细胞比例并最终增强抗肿瘤疗效。
临床怎么用
- 早期监测naïve样新鲜T细胞状态可能有助于预判格菲妥单抗疗效。
- 联合4-1BB共刺激是克服T细胞衔接器耐药、改善侵袭性淋巴瘤应答的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell engagers (TCEs) have recently transformed the therapeutic landscape of hematological malignancies, including relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). However, the variability in patient responses underscores the need for a deeper mechanistic understanding of the factors driving efficacy. Immune cell composition and T-cell functional states are emerging as critical determinants of immunotherapy outcomes. Recent advances in single-cell RNA sequencing (scRNA-seq) technologies have enabled high-resolution characterization of T-cell states, revealing a spectrum from highly activated effectors to exhausted or dysfunctional subsets within the tumor microenvironment. In this study, we conducted longitudinal scRNA-seq analyses and functional assessments of peripheral blood immune cells (peripheral blood mononuclear cells [PBMCs]) from patients with glofitamab-treated R/R B-NHL, achieving complete metabolic response, or with progressive metabolic disease. Our findings reveal that the maintenance of naïve-like ("fresher") T-cell states (particularly the fresher cytotoxic T cells) at early time points is associated with clinical efficacy. In line with molecular data, T cells from responders exhibited enhanced functional activity compared with nonresponders. Furthermore, the analysis of patient PBMCs and intratumor T cells from preclinical tumor models after consecutive glofitamab treatments revealed sustained functional activity, underscoring the long-term durability of T-cell responses. Combination of glofitamab with 4-1BB costimulation translated into increased proportions of intratumor T cells having a fresher, naïve-like phenotype, ultimately leading to stronger antitumor efficacy. Taken together, our findings underscore the therapeutic relevance of fresher, naïve-like T-cell states and the potential of leveraging 4-1BB costimulation to overcome TCE resistance and improve clinical responses in aggressive lymphomas.
引用
- Schmeing S, Nassiri S, Leclercq-Cohen G, et al. Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma. Blood Adv. 2026. PMID: 41569641. doi:10.1182/bloodadvances.2025016925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。